



R Stahel

Contact

R Stahel

Publications (8)

Gachechiladze M, Überall I, Skanderová D, Matchavariani J, Ibrahim M, Shani I, Smičková P, Kolek V, Cierna L, Kleine-Tebbe J, Stahel R, Joerger M, Soltermann A, Škarda J. LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinoma. *Lung Cancer* 2021; 156:129-135.

Stahel R, Thatcher N, Früh M, Le Péchoux C, Postmus P, Sorensen J, Felix E, Panel members. 1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. *Ann Oncol* 2011; 22:1973-1980.

Felip E, Gridelli C, Baas P, Rosell R, Stahel R, Panel members. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. *Ann Oncol* 2011; 22:1507-1519.

Martinelli G, Zucca E, Dietrich P, Lohri A, Vorobiof H, Heizmann M, Stahel R, Stupp R, Okkinga E, Hess U, Cerny T, Utiger U, Schmitz S, Ghielmini M. Long term follow up of patients with follicular lymphoma receiving single agent rituximab at 2 different schedules in trial SAKK 35/98. *J Clin Oncol* 2010; 28:4480-4484.

Betticher D, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris H, Stahel R, Spiliopoulos A, Roth A, Hsu Schmitz S, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R, Pless M, Habicht J, Swiss Group for Clinical Cancer Research (SAKK). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. *British journal of cancer* 2006; 94:1099-106.

Ghielmini M, Cerny T, Wernli M, Ketterer N, Lohri A, Stahel R, Martinelli G, Fey M, Cogliatti S, Léger-Falandry C, Leoncini-Francini L, Salles G, Rufibach K, Schmitz S. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2005; 16:1675-82.

Fogliata A, Schefer H, Curti G, Schott A, Zenklusen H, Roth A, Morel P, Gertsch P, Gervaz P, Davis J, Székely G, Burger C, Huser M, Kolotas C, Thalmann G, Guillou L, Jichlinski P, von Briel C, Beer K, Miralbell R, Escudé L, Mollà M, Nouet P, Rouzaud M, Mini R, Kemmerling L, Vetterli D, Lütolf U, Ulmer U, Oehler C, Weber D, Bolsi A, Lomax A, Timmermann B, Goitein G, Verwey J, Pedroni E, Rutz H, Lomax A, Weber D, Luthi F, Pasche P, Bentzen S, Khalil A, Dubois J, Pica A, Stupp R, Stadelmann O, Allaoua M, Kebdani T, Slosman D, Dische S, Cummings B, Van den Bogaert W, Horiot J, Saunders M, Isaak B, Pesce G, Popowski Y, Tebeu P, Matzinger O, Betz M, Corminboeuf F, Bouville S, Özsoy O, Bigler R, Veas H, Girardet C, Abdou M, Huguenin P, Verkooijen H, Bouchardy C, Franzetti A, Richetti A, Presilla S, Motta M, Valley J, Bressan S, Bulling S, Pache G, Merçay A, Major A, Usel M, Ludicke F, Rufibach K, Ries G, Coucke P, Wang H, Pasche G, Do H, Balmer A, Munier F, Jargy C, Dipasquale G, Born E, Szczerba D, Hueber P, Hafner H, Cozzi L, Moeckli R, Boehringer T, Collen T, Luluhová D, Allemann K, Bründler M, Krayenbühl J, Schoenmaker E, Norton I, Baumert B, Rutz H, Pedroni E, Lin S, Coray A, Nicolini G, Veas H, Martineau P, Gourgou S, Zouhair A, Ozsahin M, Cunat S, Larbouret C, Azria A, Bonny C, Hofstetter B, Tenzer A, Krek W, Lutters G, Evans D, Romieu G, Bodis S, Stahel R, Weder W, Jerman M, Schneiter D, Jörgler M, Lardinois D, Taverna C, Kestenholz P, Heuberger J, Pèlerin A, Pujol P, Zimmer Y, Greiner R, Gruber G, Ametamey S, Bodis S, Zingg D, Jochum W, Vuong V, Honer M, Riesterer O, Mhawech P, Verdan C, Tschanz E, Dulguerov P, Ares C, Pruschy M, Inteeworn N, Stalder D, Streit B, Ganapathipillai S, Aebersold D, Berthou S, Kaser-Hotz B, Gassmann M, Rohrer Bley C, Wergin M, Roos M, Höpfl G, Ohlerth S, Allal A, Behrensmeier F, Thürlimann B, Carbone A, Crivellari D, Collins J, Gol-Ouh R, Lindtner J, Holmberg S, Rudenstam C, Castiglione-Gertsch M, Price K, Nasi M, Bonetti M, Simoncini E, Fey M, Bortoluzzi L, Weitzel M, Kranzbuehler H, Becker M, Taussky D, Azria D, Mirimanoff R, Kramar A, Jeanneret Sozzi W, Goldhirsch A, Coates A, Gelber R, UELTSCHI G, Lippold B, Kranzbühler H, Bernier J, Studer G, Landmann C, Mahler F, Greiner R, Taverna C, Stanek N, Ciernik I, Friedrich E, Beer K, Balmer Majno S, Hügli A, Gallino A, Juelke P, Pajic B, Curschmann J, Bieri S, Luthi J, Suleiman M, Bargetzi M, Notter M, Thum P, Resink T, Erne P, Jamshidi P, Hafner H, Mach N. Abstracts from the 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO). *Strahlenther Onkol* 2004; 180 Suppl 1:89-108.

Joss R, Stahel R, Martinelli G, Cerny T, Thürlimann B, Leyvraz S, Bacchi M, Hürny C, Alberto P, Ludwig C. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK). *Annals of oncology* : official journal of the European Society for Medical Oncology / ESMO 1995; 6:41-8.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch